Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 4

Meropenem in the treatment of complicated skin and soft tissue infections

Authors Douglas N Fish

Published 15 December 2006 Volume 2006:2(4) Pages 401—415

Douglas N Fish
Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado, USA
Abstract: Meropenem is a broad-spectrum carbapenem antibiotic with excellent activity against many pathogens associated with complicated skin and soft tissue infections (cSSTIs). At least three studies have shown meropenem to have good clinical efficacy and to be well tolerated in the treatment of cSSTIs. Two open-label studies compared meropenem 500 mg every 8 hours (total evaluable n=146) with imipenem/cilastatin 500 mg every 6 hours (n=147). Clinical efficacy rates in evaluable patients 7–14 days after end of treatment were similar, 92% and 100% in meropenem-treated groups versus 89% and 100% in groups receiving imipenem/cilastatin. An additional prospective, randomized, double-blind study evaluated meropenem 500 mg every 8 hours (261 evaluable patients) versus imipenem/cilastatin 500 mg every 8 hours (287 patients). Clinical efficacy rates of meropenem and imipenem/cilastatin 7–28 days after end of treatment were 86.2% and 82.9%, respectively. Meropenem was well tolerated in all studies. Carbapenems are currently recommended as appropriate for initial treatment of certain cSSTIs such as those likely to involve mixed and/or multidrug-resistant pathogens. Meropenem is an effective and safe alternative for monotherapy when used for appropriate types of cSSTIs. Higher doses (ie, 1 g every 8 hours) should be considered for treatment of cSSTIs in higher-risk patients where Pseudomonas aeruginosa is a suspected or documented pathogen.
Keywords: meropenem, carbapenems, wound infection, diabetic foot, antibiotics, nosocomial infection

Download Article [PDF] 

Readers of this article also read:

Clinical utility of eslicarbazepine: current evidence

Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A

Drug Design, Development and Therapy 2015, 9:781-789

Published Date: 10 February 2015

Absorbable stent: focus on clinical applications and benefits

Gonzalo N, Macaya C

Vascular Health and Risk Management 2012, 8:125-132

Published Date: 29 February 2012

Pharmacological management of acute bronchiolitis

Melvin Wright, Charles J Mullett, Giovanni Piedimonte

Therapeutics and Clinical Risk Management 2008, 4:895-903

Published Date: 10 October 2008

“One pill, once daily”: what clinicians need to know about Atripla™

Patrick G Clay, Tracey AH Taylor, Alan G Glaros, MaryPeace McRae, Charlott Williams, et al

Therapeutics and Clinical Risk Management 2008, 4:291-302

Published Date: 11 April 2008

House dust mite control measures in the treatment of asthma

Gillian Vallance, Charles McSharry, Stuart Wood, Neil C Thomson

Therapeutics and Clinical Risk Management 2006, 2:347-354

Published Date: 15 December 2006

Cost-benefit analysis of influenza vaccination in a public healthcare unit

Giorgio L Colombo, Antonio Ferro, Marta Vinci, Maria Zordan, Giulio Serra

Therapeutics and Clinical Risk Management 2006, 2:219-226

Published Date: 15 June 2006